title: Plantibodies: applications, advantages and bottlenecks.
abstract: Various strategies have been developed to exploit plants as bioreactors for the production of pharmaceutical antibodies, to engineer antibody-mediated pathogen resistance or to alter the plant phenotype by immunomodulation. Recent research developments focus on the fine-tuning of expression systems and the detailed characterisation of recombinant products, including the implications of plant-specific glycosylation. Meanwhile, the first of these plant-derived antibody products has successfully completed early phase clinical trials.
authors.affiliation: Molecular Biotechnology Unit, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK. stoger@bbsrc.ac.uk
authors.forename: Eva
authors.initials: E
authors.lastname: Stoger
authors.forename: Markus
authors.initials: M
authors.lastname: Sack
authors.forename: Rainer
authors.initials: R
authors.lastname: Fischer
authors.forename: Paul
authors.initials: P
authors.lastname: Christou
mesh_terms: D000906:Antibodies / Q000235:genetics* / Q000276:immunology; D019149:Bioreactors; D001709:Biotechnology / Q000379:methods; D005818:Genetic Engineering / Q000379:methods; D030821:Plants, Genetically Modified / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism
chemical_list: D000906:Antibodies